Mandate

Vinge has advised Bilprovningen in connection with the sale of approx. 1/3 of its network of inspection stations

July 09, 2012

Vinge has advised Aktiebolaget Svensk Bilprovning in connection with the disposal of Besiktningskluster 1 AB to Opus Group AB (publ). Besiktningskluster 1 AB owns around 1/3 of Bilprovningen’s network of inspection stations and the disposal is part of the reregulation and competition exposure of the Swedish vehicle inspection market. Opus Group AB (publ) is listed on First North Premier (NASDAQ OMX) and develops, produces and sell products and services for, inter alia, vehicle inspections and repair workshops, and operates mandatory vehicle inspection programs in a number of countries. The purchase price amounts to approx. MSEK 375. The transaction is subject to, inter alia, accreditation approval.

The Vinge team was led by Carl Gustaf De Geer, Daniel Rosvall and Peter Sundgren and included lawyers from a number of practice areas such as M&A, Banking & Finance, EU &Antitrust, IT, Employment & Benefits, Real Estate, Intellectual Property and also entailed regulatory issues regarding the motor vehicle inspection legislation.

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025